Cancer researchers have long puzzled over c-Myc, a protein that drives tumor growth but whose cellular lifespan seemed contradictory—sometimes destroyed by one pathway, sometimes escaping through another. This molecular mystery has implications for understanding why some cancers resist treatment while others respond to targeted therapies. The research reveals that PP2A-B55α, a phosphatase complex, acts as a molecular switch determining which degradation pathway c-Myc follows. When PP2A-B55α levels are high, it removes phosphate groups from c-Myc at the critical Thr58 position, allowing the protein to evade destruction by the FBXW7 pathway that normally keeps it in check. However, this dephosphorylation simultaneously channels c-Myc toward an alternative degradation route, maintaining cellular control despite the escape from FBXW7-mediated breakdown. The findings demonstrate that PP2A-B55α concentration acts as a cellular rheostat, fine-tuning c-Myc levels through pathway switching rather than simple on-off regulation. This discovery resolves a fundamental paradox in tumor biology where PP2A appeared to both promote and prevent c-Myc degradation simultaneously. For cancer therapeutics, this suggests that targeting PP2A-B55α levels could offer a more nuanced approach to controlling c-Myc than current strategies focused on single pathways. The dual-pathway model also explains why some tumors with altered PP2A function show unexpected c-Myc behavior, potentially informing personalized treatment strategies. However, these mechanistic insights emerge from controlled laboratory conditions, and translating pathway switching dynamics into clinical interventions remains a significant challenge requiring extensive validation in human tumor models.